Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson

Circulation

Volumn 111, Issue 24, 2005, Pages 3202-3208

  Ellenbogen, Kenneth A ^a   O'Neill, Gearoid ^b   Prystowsky, Eric N ^c   Camm, John A ^d   Meng, Lixin ^e   Lieu, Hsiao Dee ^e   Jerling, Markus ^e   Shreeniwas, Revati ^e   Belardinelli, Luiz ^e   Wolff, Andrew A ^e  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Regional Cardiology Associates   (United States)

^c Care Group   (United States)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e CV THERAPEUTICS INC   (United States)

Author keywords

Adenosine; Drugs; Electrophysiology; Tachyarrhythmias; Tecadenoson

Indexed keywords

PLACEBO; TECADENOSON;

ADULT; AGED; ARTICLE; ASTHMA; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; BRONCHOSPASM; CARDIOVASCULAR SYMPTOM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FLUSHING; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART ELECTROPHYSIOLOGY; HEART TAMPONADE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PERICARDIAL EFFUSION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNCOPE; TACHYCARDIA; TREATMENT OUTCOME;

ADENOSINE; ADULT; AGED; BLOOD PRESSURE; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROPHYSIOLOGY; FEMALE; FURANS; HEART ARREST; HEART RATE; HUMANS; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; RECEPTOR, ADENOSINE A1; SYNCOPE; TACHYCARDIA, SUPRAVENTRICULAR; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 21044458444     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.510982     Document Type: Article

References (22)

1. Orejarena LA, Vidaillet H Jr, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, Hayes JJ. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998;31:150-157.
2. Hebbar AK, Hueston WJ. Management of common arrhythmias, part I: supraventricular arrhythmias. Am Fam Physician. 2002;65:2479-2486.
3. Chauhan VS, Krahn AD, Klein GJ, Skanes AC, Yee R. Supraventricular tachycardia. Med Clin North Am. 2001;85:193-223.
4. Miller JM, Zipes DP. Management of the patient with cardiac arrhythmias. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia, Pa: WB Saunders Co; 2001:700-774.
5. Lowenstein SR, Halperin BD, Reiter MJ. Paroxysmal supraventricular tachycardias. J Emerg Med. 1996;14:39-51.
6. Snowdy S, Liang HX, Blackburn B, Lum R, Nelson M, Wang L, Pfister J, Sharma BP, Wolff A, Belardinelli L. A comparison of an A, adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea-pig. Br J Pharmacol. 1999;126:137-146.
7. 1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Ther. 2001;6:237-245.
8. 1-adenosine receptor agonist. J Am Coll Cardiol. 2003;42:1098-1102.
9. SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute Inc; 1999.
10. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
11. Gausche M, Persse DE, Sugarman T, Shea SR, Palmer GL, Lewis RJ, Brueske PJ, Mahadevan S, Melio FR, Kuwata JH, Niemann JT. Adenosine for the prehospital treatment of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1994;24:183-189.
12. McCabe JL, Adhar GC, Menegazzi JJ, Paris PM. Intravenous adenosine in the prehospital treatment of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1992;21:358-361.
13. Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991;20:717-721.
14. q in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999;56:705-713.
15. Fan M, Qin W. Mustafa SJ. Characterization of adenosine receptor(s) involved in adenosine-induced bronchoconstriction in an allergic mouse model. Am J Physiol Lung Cell Mol Physiol. 2003;284:L1012-L1019.
16. Spicuzza L, Bonfiglio C, Polosa R. Research applications and implications of adenosine in diseased airways. Trends Pharmacol Sci. 2003; 24:409-413.
17. Adenocard [prescribing information]. Deerfield, Ill: Fujisawa Healthcare, Inc: August 2003.
18. 1 adenosine receptor ligands. Curr Top Med Chem. 2003;3:369-385.
19. Tebbenjohanns J, Schumacher B, Pfeiffer D, Jung W, Luderitz B. Dose and rate-dependent effects of adenosine on atrial action potential duration in humans. J Interv Card Electrophysiol. 1997;1:33-37.
20. Kabell G, Buchanan LV, Gibson JK, Belardinelli L. Effects of adenosine on atrial refractoriness and arrhythmias. Cardiovasc Res. 1994;28: 1385-1389.
21. Glatter KA, Cheng J, Dorostkar P, Modin G, Talwar S, Al-Nimri M, Lee RJ, Saxon LA. Lesh MD, Scheinmann MM. Electrophysiologie effects of adenosine in patients with supraventricular tachycardia. Circulation. 1999;99:1034-1040.
22. Strickberger SA, Man KC, Daoud EG, Goyal R, Brinkman K, Knight BP, Weiss R, Bahu M, Morady F. Adenosine-induced atrial arrhythmia: a prospective analysis. Ann Intern Med. 1997;127:417-422.